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Comparative data regarding different regimens of oral mesalazine (mesal-
amine) for maintaining remission in ulcerative colitis are limited.
Aim
To evaluate whether 3.0 g mesalazine once-daily (OD) is superior to the
standard treatment of 0.5 g mesalazine three times daily (t.d.s.) and
to prove the therapeutic equivalence of OD vs. t.d.s. dosing of total 1.5 g
mesalazine for remission maintenance in patients with ulcerative colitis.
Methods
A 1-year, multicentre, double-blind, double-dummy study was undertaken
in patients with endoscopically and histologically confirmed ulcerative coli-
tis in remission. Patients were randomised to oral mesalazine 3.0 g OD,
1.5 g OD or 0.5 g t.d.s. The primary efficacy endpoint was the proportion
of patients still in clinical remission at the final visit, with clinical relapse
being defined as CAI score >4 and an increase of ‡3 from baseline.
Results
The primary efficacy endpoint occurred in 162 ⁄ 217 3.0 g OD patients
(75%), 129 ⁄ 212 1.5 g OD patients (61%) and 150 ⁄ 218 0.5 g t.d.s. patients
(69%) in the intention-to-treat population, and in 152 ⁄ 177 (86%), 121 ⁄ 182
(67%) and 144 ⁄ 185 (78%) in the per protocol population respectively; 3.0 g
OD was superior to both low-dose regimens for the primary endpoint (i.e.
P < 0.001, 3.0 g OD vs. 1.5 g OD; P = 0.024, 3.0 g OD vs. 0.5 g t.d.s.; supe-
riority test, per protocol population). Safety analysis, including comprehen-
sive renal monitoring, revealed no concern in any treatment group.
Conclusion
Mesalazine 3.0 g once daily was the most effective dose for maintenance of
remission in ulcerative colitis of the three regimens assessed, with no pen-
alty in terms of safety.
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INTRODUCTION
Ulcerative colitis (UC) is a chronic disorder of the colon
characterised by periods of active disease followed by
asymptomatic periods (remission). Maintaining remis-
sion by prevention of relapses is a well-established objec-
tive for chronic medical management of UC, with the
aminosalicylates [sulphasalazine, mesalazine (mesal-
amine), olsalazine and balsalazide] being widely regarded
as the gold standard for maintenance therapy. Mesal-
azine, a newer aminosalicylate, is superior to placebo for
maintenance therapy,1 and because of a better safety
profile, has largely superseded sulphasalazine to become
the most commonly prescribed aminosalicylate. Never-
theless, a number of questions regarding the optimal
use of mesalazine for maintenance of remission remain
unresolved.
Data are mixed regarding a possible efficacy benefit of
increased daily dosage,2–4 and recent reviews have con-
cluded that there may be no clear dose-response relation-
ship or any incremental benefit of doses above 1.5 g ⁄ day
for maintenance of UC remission.5, 6 Studies of compli-
ance with delayed-release mesalazine in inflammatory
bowel diseases revealed three-times daily (t.d.s.) dosing
to be an independent predictor of noncompliance.7 Mul-
tiple daily dosing may thus limit the rate of sustained
remission with mesalazine in patients with UC.8
Several formulations of mesalazine are available.
Salofalk granules (Dr Falk Pharma GmbH, Freiburg,
Germany) differ from other mesalazine formulations by
combining both delayed- and extended-release mecha-
nisms. First, mesalazine release is delayed until pH ‡6.0
due to an enteric, acid-resistant film coating, such that
absorption in the upper gastrointestinal tract is pre-
vented. Second, because of inner polymer matrix the me-
salazine release is prolonged throughout the entire
colon.9
We report here the results of a one-year, multicentre,
randomised, double-blind, double-dummy study in
which we evaluated the efficacy and safety of mesalazine
(Salofalk granules) using three different dosing regimens
(3.0 g OD, 1.5 g OD or 0.5 g t.d.s.) for maintenance of
remission in UC patients.
METHODS
Protocol
This was a 1-year, randomised, double-blind, double-
dummy, parallel-group, multicentre, phase III study con-
ducted at 65 gastroenterology centres in 13 countries
(see Appendix). The study started in May 2005 and com-
pleted in April 2007. The study was performed in accor-
dance with the principles of Good Clinical Practice and
the Declaration of Helsinki and was approved in each
participating country by a central Independent Ethics
Committee and ⁄ or local Independent Ethics Committees.
Written informed consent was obtained from each
patient. The study was registered at ClinicalTrials.gov
(NCT00746447).
Participants
Male and female patients aged between 18 and 75 years
were eligible to take part in the study if (i) they had an
endoscopically and histologically confirmed diagnosis of
UC with mucosal inflammation extending at least 15 cm
beyond the anal margin during the last active episode,
(ii) the last active episode had ended within the
3 months prior to study entry and (iii) they were in
remission as defined by Clinical Activity Index (CAI)
£4,10 and Endoscopical Index (EI) £3.10 Patients with
Crohn’s disease, toxic megacolon, impaired renal func-
tion, serious comorbidity, use of immunosuppressants
within 3 months prior to study entry or use of glucocort-
icosteroids within 1 month prior to study entry were
excluded.
Assignment
Randomisation was performed centrally in blocks of
three by means of a computer-generated randomisation
list. The randomisation list was sealed and held by bio-
statistical staff of ClinResearch GmbH who were not
involved in the study conduct.
Masking
Mesalazine 3.0 g OD was administered as two sachets
each containing 1.5 g mesalazine in the morning and
one sachet containing 0.5 g placebo at noon and in the
evening; 1.5 g OD was administered as two sachets each
containing 0.75 g mesalazine and 0.75 g placebo in the
morning and one sachet containing 0.5 g placebo at
noon and in the evening; and 0.5 g t.d.s. was adminis-
tered as two sachets each containing 0.25 g mesalazine
and 1.25 g placebo in the morning and one sachet
containing 0.5 g mesalazine both at noon and in the
evening.
Concomitant medication
The following medications were not allowed during the
study: steroids, antibiotics, immunosuppressants, non-
steroidal anti-inflammatory drugs, other aminosalicylate
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treatments, loperamide, psyllium-containing drugs or
de novo treatment with probiotics.
Study objective and endpoints
The objective was to evaluate whether 3.0 g mesalazine
OD is superior to the standard treatment of 0.5 g mesal-
azine t.d.s. and to prove the therapeutic equivalence of
OD vs. t.d.s. dosing of total 1.5 g mesalazine for remis-
sion maintenance in patients with UC. The primary effi-
cacy endpoint was the proportion of patients still in
clinical remission at the final visit, with clinical relapse
being defined as CAI score >4 and an increase of ‡3
from baseline. Secondary efficacy endpoints included the
proportion of patients in clinical remission at month 12
among the subpopulation with signs of mucosal inflam-
mation at baseline endoscopy, i.e. patients with an EI
score >1 at baseline (EI £1 represents ‘normal mucosa
or at maximum faded ⁄ disturbed vascular pattern; no fri-
ability’), endoscopic remission at month 12 based on the
EI, and the change from baseline to month 12 in the
number of stools and the number of bloody stools per
week. Safety endpoints included the occurrence of
adverse events and altered laboratory parameters with a
focus on renal monitoring. In addition, trough levels of
mesalazine and N-acetyl-mesalazine in plasma were
monitored in a subgroup of patients. At the end of the
treatment period, patients were asked if they preferred
OD or t.d.s. dosing, although all patients were required
to follow t.d.s. dosing because of the double-dummy
study design.
Evaluation
Study visits took place on day 0 (baseline) and at weeks
4, 12, 24, 36 and 52 (final visit). If patients discontinued
the study prematurely, a full final visit was performed if
possible. Patients were given a paper diary containing
eight items to be completed throughout the study. Clini-
cal signs of UC (e.g. number of stools per day and num-
ber of bloody stools per day) and safety and tolerability
were assessed at each visit. Endoscopy was performed at
the baseline and final visits.
Plasma concentrations of mesalazine and N-acetyl-
mesalazine were measured by validated liquid chroma-
tography tandem mass spectrometry.11 Lower limits of
quantification were 10 ng ⁄ mL in plasma for both
analyses. The within-day and between-day coefficients of
variation were below 10%; accuracy of the assay in
plasma was in the range 98–105%.
Compliance with study medication was recorded by
checking the study medication returned at each study
visit and by monitoring the patient diaries. Patients were
considered to be compliant if the ratio of the number of
administered sachets to the scheduled number of sachets
was >75%.
Analysis
The sample size calculation was based on a non-inferior-
ity comparison of the 1.5 g OD group vs. the 0.5 g t.d.s.
group. For one-sided a = 0.025 with a non-inferiority
margin of 15% and assuming that the absolute and
assumed proportion of patients with clinical remission at
the final visit would be 60% in both groups, a population
of 166 patients per group in the per protocol (PP) popu-
lation was estimated to have 80% power to detect
non-inferiority. Assuming that 17% of patients in the
intention-to-treat (ITT) population would be excluded
from the PP population (the primary analysis popula-
tion), the planned sample size was 200 patients per treat-
ment group. This sample size also provided 83% power
to detect superiority for 3.0 g OD vs. any of the lower
dose groups.
Confirmatory testing was performed for the primary
efficacy endpoint comparison of the 1.5 g OD and 0.5 g
t.d.s. groups, using the asymptotic Chi-squared test. All
other comparisons were exploratory. The primary analy-
sis was performed on the PP population and repeated
for the ITT population. In addition, superiority of mesal-
azine 3.0 g OD vs. 0.5 g t.d.s. and 1.5 g OD, respectively,
was assessed on the primary efficacy endpoint of clinical
remission at the final visit in the ITT population and
repeated for the PP population.
For the primary efficacy endpoint, patients who dis-
continued the study prematurely were calculated as non-
responders. For secondary efficacy variables the last
observation carried forward (LOCF) approach was used.
The ITT and safety population comprised all rando-
mised patients who received at least one dose of study
medication. The PP population was defined as a subset
of ITT excluding all patients with major protocol viola-
tions as well as patients who were noncompliant with
the study medication.
Quantitative variables are described using
mean  standard deviation (s.d.) and ⁄ or median (range)
as appropriate. Qualitative variables are described by fre-
quency. Where appropriate, 95% confidence intervals
(CIs) are provided for differences between treatment
groups for secondary efficacy variables. For comparison
of baseline and end of treatment values of renal and
pharmacokinetic parameters, a two-sided Wilcoxon sign
rank test for one sample was used. Kruskal–Wallis test
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was used for comparing pharmacokinetic parameters
between the three different treatment groups. The level
of significance was set at P < 0.05.
Biometric analyses were undertaken using the SAS sta-
tistical software package (version 9.1.3, SAS Institute
Inc., Cary, NC, USA).
RESULTS
Patient disposition
In total, 648 patients were randomised (3.0 g OD: 218;
1.5 g OD t.d.s.: 212; 0.5 g t.d.s.: 218). Thereof, 204
patients (94%), 207 patients (98%) and 211 patients
(97%) of the 3.0 g OD group, the 1.5 g OD group and
the 0.5 g t.d.s. group, respectively, were compliant. One
patient, randomised to the 3.0 g OD group, did not
receive any study medication and was excluded from all
analyses. Thus, the ITT and safety populations com-
prised 647 patients, of whom 496 (77%) completed the
study (Figure 1). One hundred and four patients were
excluded from the PP population, which consisted of 544
patients. The most frequent protocol deviations that led
to exclusion from the PP population were intake of study
medication for less than 4 weeks (n = 27), last acute epi-
sode of UC not ending within 3 months prior to study
entry (n = 14), CAI not £4 at study entry (n = 13) and
>21 days without study medication before the final or
withdrawal examination (n = 12). The reasons for exclu-
sion from the PP population did not differ significantly
between treatment groups. The number of patients com-
pleting the study in each group are shown in Figure 1.
History of the patients of the three groups showed some
slight differences, demonstrating long-standing disease
(>5 years) and a shorter interval of remission prior to
entry to the study to occur more often in the 1.5 g OD
group. Altogether, the three treatment groups showed no
significant differences for demographic and anamnestic
characteristics at baseline and previous treatment
(Table 1).
Treatment compliance
Treatment compliance (i.e. ratio of administered sachets
to scheduled sachets >75%) was reported in 204 patients
(94%), 207 patients (98%) and 211 patients (97%) of the
3.0 g OD group, the 1.5 g OD group and the 0.5 g t.d.s.
group, respectively.
Efficacy
The primary efficacy endpoint, clinical remission at the
final visit, occurred in 162 ⁄ 217 3.0 g OD patients (75%),
129 ⁄ 212 1.5 g OD patients (61%) and 150 ⁄ 218 0.5 g
t.d.s. patients (69%) (ITT population). Similar results
were observed in the PP population, with clinical remis-
sion in 152 ⁄ 177 patients (86%), 121 ⁄ 182 patients (67%)
and 144 ⁄ 185 patients (78%), respectively. In both analy-
sis sets, 3.0 g OD achieved the highest remission rates.
Superiority testing showed a significantly higher rate of
the primary efficacy endpoint in the 3.0 g OD group vs.
the 1.5 g OD group in both the ITT population and the
PP population. The 3.0 g OD regimen was also superior
648 randomized
1 did not receive 
study medication
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Figure 1 | Patient disposition.
ITT, intention-to-treat; PP, per
protocol.
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Male gender, n (%) 107 (49) 104 (49) 108 (50)
Age (years),
mean  s.d.
45.2  14.0 45.5  14.2 43.6  14.0
Body mass index
(kg ⁄m2), mean  s.d.
25.2  3.9 25.2  4.2 25.2  4.0
Caucasian, n (%) 217 (100) 210 (99) 218 (100)
Smoker, n (%) 23 (11) 12 (6) 19 (9)
Disease duration (years),
median (range)
3.6 (0.1–43.8) 4.2 (0.2–36.6) 3.9 (0.2–42.4)
Disease duration
‡5 years, n (%)
87 (40) 100 (47) 90 (41)
Daily stool frequency,
mean  s.d.
1.6  0.9 1.5  0.7 1.6  1.0
Number of previous episodes, mean  s.d.
Total 4.7  5.5 (n = 216) 5.2  5.4 (n = 211) 5.1  7.5 (n = 215)
Last year 1.3  0.7 (n = 210) 1.3  0.7 (n = 206) 1.3  0.6 (n = 215)
Duration of last acute
episode (days), mean
[95% CI]
96 [74; 117] 80 [71; 89] 113 [78; 147]
Time from start of
current remission phase
until day 0 (days),
mean [95% CI]
57 [37; 78] 43 [35; 51] 67 [36; 97]
Last acute treatment, n (%)*
Oral mesalazine 161 (74) 164 (77) 171 (78)
Rectal mesalazine 58 (27) 61 (29) 49 (23)
Oral sulphasalazine 42 (19) 45 (21) 40 (18)
Oral steroids 19 (9) 13 (6) 22 (10)
Rectal steroids 5 (2) 6 (3) 7 (3)
Intravenous steroids – 1 (1) 2 (1)
Oral budesonide 1 (1) 1 (1) 5 (2)
Rectal budesonide 1 (1) 2 (1) 1 (1)
Immunosuppressants 1 (1) – –
Clinical Activity Index
(CAI), mean  s.d.
1.2  1.5 1.2  1.5 1.2  1.4
Endoscopical Index
(EI), mean  s.d.
1.6  1.2 1.7  1.2 1.6  1.1
EI, n (%)
EI £1 119 (55) 109 (51) 120 (55)
EI >1 98 (45) 103 (49) 98 (45)
* Multiple entries per patient were possible.
 EI £1 represents normal mucosa or at maximum faded ⁄ disturbed vascular pattern; no friability.
Randomised clinical trial: once daily 3 g mesalazine for maintenance of UC
Aliment Pharmacol Ther 2011; 33: 313–322 317
ª 2010 Blackwell Publishing Ltd
to the 0.5 g t.d.s. group in the PP population, and
slightly exceeded the significance in the ITT population.
Non-inferiority of 1.5 g OD vs. 0.5 g t.d.s. was not
achieved at the predefined 15% non-inferiority margin.
Similar results were observed in the ITT population. For
details see Figure 2.
When the primary efficacy endpoint was analysed post
hoc in the subpopulation of patients with signs of muco-
sal inflammation at baseline endoscopy, i.e. having an EI
score of >1 at baseline, mesalazine 1.5 g OD was found
to be statistically not different to 0.5 g t.d.s.; 3.0 g OD
was superior to both low-dose treatment groups (Fig-
ure 3a). Interestingly, 3.0 g OD did not gave an
additional clinical benefit in patients being in deep endo-
scopic remission (i.e. EI £1) at baseline (Figure 3b), sug-
gesting that a low-dose treatment with mesalazine is
sufficient in these patients.
Approximately 70% of patients were still in endo-
scopic remission (EI £3) at 12 months (LOCF method),
with no significant differences between treatment groups
(Figure 4). Consistent with this, equal proportions of
patients were in deep endoscopic remission (EI £1)
at 12 months (LOCF method), with no significant



















































































Figure 2 | Primary efficacy endpoint (proportion of
patients in clinical remission at final visit, with relapse
defined as CAI >4 and ‡3 increase from baseline)
according to treatment group for (a) intention-to-treat
(ITT) population, *superiority test, 95% CI for differ-
ence [)0.026; 0.143]; **superiority test, 95% CI for dif-
ference [0.050; 0.225]; ***non-inferiority test, 95% CI
for difference [)0.169; 0.011]; and (b) per protocol [PP]
population, *superiority test, 95% CI for difference
[0.001; 0.160]; **superiority test, 95% CI for difference




















































































Figure 3 | Post hoc analysis of the primary efficacy end-
point (proportion of patients in clinical remission at
final visit, with relapse defined as CAI >4 and ‡3
increase from baseline) according to treatment group in
the subpopulation of patients with (a) signs of mucosal
inflammation (EI >1) at baseline [intention-to-treat
(ITT) population] *superiority test, 95% CI for differ-
ence [)0.013; 0.237]; **superiority test, 95% CI for dif-
ference [0.057; 0.309]; *** superiority test, 95% CI for
difference [)0.204; 0.062] and (b) no signs of mucosal
inflammation (EI £1, i.e. deep endoscopic remission) at
baseline (ITT) *superiority test, 95% CI for difference
[)0.100; 0.129]; **superiority test, 95% CI for differ-
ence [)0.023; 0.220]; ***superiority test, 95% CI for
difference [)0.206; 0.038].
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115 ⁄ 217 (53%), 1.5 g OD group: 108 ⁄ 212 (51%), 0.5 g
t.d.s. group: 115 ⁄ 218 (53%)].
The 3.0 g OD cohort showed the smallest increase in
the number of stools per week [mean  s.d.: 3.0 g OD
1.1  9.8, 1.5 OD 4.4  14.6 (P = 0.005 vs. 3.0 g OD),
0.5 g t.d.s. 2.2  12.9 (P = NS)] and the smallest
increase in the number of bloody stools per week
[mean  s.d.: 3.0 g OD 1.7  6.9, 1.5 g OD 5.8  13.1
(P < 0.001 vs. 3.0 g OD), 0.5 g t.d.s. 3.7  12.7
(P = 0.043 vs. 3.0 g OD)].
The majority of all patients (519 ⁄ 647, 80%) clearly
favoured an OD schedule, whereas only 22 ⁄ 647 patients
(3%) preferred a t.d.s. schedule; 86 ⁄ 647 patients (13%)
had no preference and 20 ⁄ 647 patients (3%) did not
comment. There were no differences seen between the
treatment groups.
Safety and tolerability
In total, 146 adverse events (AEs) occurred in 89 patients
(41%) in the 3.0 g OD group, 154 AEs in 117
patients (55%) in the 1.5 g OD group and 156 AEs in 105
patients (48%) in the 0.5 g t.d.s. group. The most frequent
types of AEs were gastrointestinal disorders, including
deterioration of UC. Serious AEs were reported in eight
patients (4%) in the 3.0 g OD group, seven patients (3%)
in the 1.5 g OD group and six patients (3%) in the 0.5 g
t.d.s. group, none of which was assessed as related to study
medication. Cystatin C, the most sensitive parameter to
detect early impairment of renal function,12 increased
above normal in one patient each in the 1.5 g OD and
0.5 g t.d.s. groups, but in no patient in the 3.0 g OD group.
Results of renal monitoring are summarised in Table 2.
Monitoring of trough concentrations of mesalazine
and its main metabolite, N-acetyl-mesalazine, did not
suggest any systemic drug accumulation over the 1 year
treatment (see Table 3). None of the statistical compari-
sons of trough levels within or between treatment groups
showed a significant difference.
DISCUSSION
This three-arm study with novel dual release mesalazine is
the first trial to evaluate a high-dose OD vs. a low-dose
OD and vs. a standard low-dose t.d.s. regimen of oral
mesalazine for the prevention of clinical relapse in UC
patients in remission using a randomised, double-blind
and double-dummy design. An excellent rate of clinical
remission maintenance was achieved in the 3.0 g OD
group (75%) using Salofalk granules. However, the study
failed to demonstrate non-inferiority for 1.5 g OD mesal-
azine compared with a standard 0.5 g t.d.s. regimen in





































P = 0.375** P = 0.832***
68.7 64.6 65.6
Figure 4 | Endoscopic remission (EI £3) at final visit
(LOCF method) according to treatment group. *superi-
ority test, 95% CI for difference [)0.058; 0.119];
**superiority test, 95% CI for difference [)0.049;
0.130]; ***superiority test, 95% CI for difference
[)0.100; 0.080].
Table 2 | Renal parameters at baseline and final visit (mean  s.d.)
Normal
range
3.0 g OD (n = 216) 1.5 g OD (n = 211) 0.5 g t.d.s. (n = 217)
Baseline Final visit Baseline Final visit Baseline Final visit
Creatinine clearance
(mL ⁄min ⁄ 1.73 m2)
>90 104  29 107  28** 100  25 102  26* 105  27 107  29**
Cystatin C (lg ⁄mL) <1.44 0.74  0.13 0.79  0.15** 0.73  0.12 0.79  0.15 ** 0.73  0.13 0.79  0.16**
a1-microglobulin
(mg ⁄ g urine
creatinine)
£16.0 5.8  5.6 5.4  6.3 5.1  4.8 5.4  6.5 4.9  4.9 4.7  6.2
b-N-acetyl-D-
glucosaminidase
(U ⁄ g urine
creatinine)
£5.0 3.5  1.8 3.3  2.2 2.9  1.5 2.9  1.6 3.1  2.5 2.9  2.0*
* P < 0.05 vs. baseline; ** P < 0.001 vs. baseline (Wilcoxon).
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would have been ideal to have included a treatment arm in
which 1.0 g mesalazine was administered t.d.s., but inclu-
sion of a fourth patient group was felt to be impractical.
The difference in clinical remission rate was most evi-
dent in patients with slight inflammation on endoscopy
at baseline. Patients with signs of mucosal inflammation
despite clinical remission have been shown to experience
a higher rate of clinical relapse than those with complete
mucosal healing,13 a finding that was confirmed in our
study. In a post hoc analysis, we observed that in patients
with slightly inflamed mucosa at baseline (i.e. EI 2-3),
3.0 g OD continued to maintain a high rate of clinical
remission (72%) while the lower-dose regimens were less
effective. This interesting result suggests that status of
mucosa might be a prognostic factor for drug response.
Endoscopic monitoring of patients with clinically quies-
cent disease seems to be worthwhile.
To date, three published randomised trials have com-
pared OD vs. twice-daily dosing of the same amount of
oral mesalazine for maintenance of clinical remission in
UC patients.13–15 Whereas one study demonstrated
significant superiority of OD dosing,14 another study
showed numerically better results for divided daily
dosing,13 while the third study showed exactly the same
numbers in both groups.15
A direct comparison of clinical remission rates between
our study and the three previous studies investigating me-
salazine OD regimens for maintenance of remission of
UC,13–15 is not reliable because of overt differences in
study design, endpoints, galenical formulations and
dosing. Obviously, an open-label,13 or single-blinded
design14, 15 is subject to bias towards overestimating a
treatment effect in the OD treatment group compared
with a double-blind, double-dummy design such as that
used in our study, where patients in the OD groups had to
administer trial medication three times daily (active in the
morning, placebo at noon and in the evening) for blinding
purposes. Whereas the open-label study concluded that
mesalazine 2.4 g ⁄ day administered as a single or divided
dose demonstrated a good safety profile, was well tolerated
and was effective as maintenance treatment, the single-
blind study concluded that oral mesalazine 2.0 g OD had
better remission rates, acceptability, and self-reported
adherence to therapy compared with patients given oral
mesalazine 1.0 g twice daily.13, 14
Furthermore, it should be borne in mind that the full
potential of a mesalazine OD maintenance regimen com-
pared with a divided dose regimen will have been missed
because all treatment groups adhered nearly perfectly to
the treatment over 1 year. Such high adherence rates are
typical for a well-controlled clinical trial setting, but do not
reflect the real-life situation, where lack of adherence is
found in about 50% of patients over 1 year,16 and is clearly
one of the driving factors for treatment failure with mesal-
azine. Thus even if a t.d.s. dose regimen would be slightly
(8%) superior in maintaining remission compared with an
OD regimen at the same daily mesalazine dose as sug-
gested in our study, better adherence to the simpler OD
regimen might compensate for the small disadvantage in
clinical practice and might be the preferred long-term
strategy. The efficacy of granulated mesalazine 1.5 g given
once a day has previously been demonstrated in a large
phase III randomised, double-blind, placebo-controlled
study involving 305 patients with inactive UC, in which
79% of patients receiving 1.5 g OD stayed relapse-free for
6 months compared with only 58% given placebo.17
Our study failed to demonstrate non-inferiority of 1.5 g
OD compared with a standard 0.5 g t.d.s. regimen in
maintaining remission. The two patient populations may
be different because of the relapse risk. A shorter interval
between end of the preceding acute episode and study
entry in the 1.5 g OD group might have promoted a
higher risk of early relapse. Similarly, the 1.5 g OD group
had the highest number of patients with long-standing
disease (47% vs. 41% in the 0.5 g t.d.s. group), indicating
that these patients were less likely to achieve remission.







Week 2 Week 52 Week 2 Week 52 Week 2 Week 52
Mesalazine [ng ⁄mL] 646 [0–1295] 797 [68–1526] 224 [28–421] 197 [54–341] 215 [34–395] 326 [0–731]
N-acetyl-mesalazine
[ng ⁄mL]
1122 [396–1847] 1280 [290–2270] 732 [361–1103] 663 [270–1057] 981 [466–1496] 844 [176–1512]
Blood samples were drawn in the morning prior administration of the study medication. All comparisons within treatments
(Mann–Whitney) and between treatments (Kruskal–Wallis) were not statistically significant.
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Once daily administration of mesalazine (3.0 g or
1.5 g) was as safe as the standard 0.5 g t.d.s. regimen. The
favourable long-term safety of the three tested regimens is
substantiated by the results of renal and trough level mon-
itoring. Nephrotoxicity, in particular tubular toxicity,
might be of concern during long-term treatment with high
doses of mesalazine.18 The shortcomings of serum creati-
nine as a marker of renal function are well recognised and
therefore estimation of glomerular filtration rate and
quantification of serum cystatin C and urinary protein
excretion were also performed. a1-microglobulin is one of
the most common indicators of tubular proteinuria and b-
NAG was demonstrated to give an early indication of
direct damage of tubular cells.19 We did not detect tubular
toxicity in any of the study patients. However, because of
the slight increase in cystatin C in each treatment group, it
remains prudent to monitor renal function every
3 months during long-term administration of mesalazine.
Our results are in accordance with a new systematic
review showing that the incidence of nephrotoxicity in
inflammatory bowel disease patients receiving mesalazine
appears to be less than 1%, with reactions being idiosyn-
cratic rather than dose-related.20
The favourable long-term safety of the three tested
regimens is substantiated by the results of drug monitor-
ing. Trough levels of mesalazine and its metabolite in
plasma during 1 year of treatment are in agreement with
our corresponding pharmacokinetic trial demonstrating
lack of systemic drug accumulation of OD mesalazine
(3.0 g or 1.5 g) over time.21
In conclusion, while all three of the assessed mesalazine
regimens are effective, mesalazine 3.0 g OD offers the
highest rate of remission maintenance in UC without a
penalty in terms of safety or tolerance. Thus, 3.0 g OD is
an appropriate dose for the maintenance of remission in
UC, particularly in patients with signs of inflammatory
activity or in whom endoscopic evidence is not available.
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